Exhibit 12.2 COMPUTATION OF RATIO OF ADJUSTED EBITDA TO INTEREST EXPENSE MEDIQ/PRN Holdings Adjusted EBITDA to interest expense: EBITDA $66,217 $66,217 SpectraCair cost savings 81 81 SpectraCair non-cash charge 573 573 CHI cost savings 1,672 1,672 -------- ------- Adjusted EBITDA $68,543 $68,543 -------- ------- -------- ------- Interest Expense $40,616 $52,879 Non-cash interest expense (1,917) (2,264) ------- ------- Interest expense (excluding deferred financing fees) $38,699 $50,615 ------- ------- ------- ------- Ratio of Adjusted EBITDA to interest expense 1.77 1.35 ------- ------- ------- ------- COMPUTATION OF RATIO OF NET DEBT TO ADJUSTED EBITDA Net Debt to Adjusted EBITDA: Total Debt $391,907 $477,085 Less: Cash (9,068) (9,203) NutraMax Note receivable 0 (5,915) -------- -------- Net Debt $382,839 $461,967 -------- -------- -------- -------- Adjusted EBITDA (per above) $ 68,543 $ 68,543 -------- -------- -------- -------- Ratio of Net Debt to Adjusted EBITDA 5.59 6.74 -------- -------- -------- --------